Sfondo Header
L'angolo del dottorino
Indice
Cerca nel sito... Ricerca avanzata
✖

Cardiac conduction disorders

Cardiac conduction disorders include conditions in which the electrical impulse propagates with delay, unevenly, or fails along part of the heart's activation system. They do not constitute a single disease: atrioventricular slowing favored by vagal tone, a lesion of the His bundle, and left bundle-branch block can produce very different electrocardiographic findings and require different decisions. The clinical problem may be failure of ventricular activation, but it may also be an inefficient contraction sequence despite an apparently normal heart rate.

Interpretation requires linking site, mechanism, and consequences. The tracing describes electrical behavior; history, time course, and imaging clarify whether that behavior reflects a functional adaptation, disease of conduction tissue, or more extensive cardiac involvement. A pacemaker is essential in some forms, unnecessary in others, and sometimes must be integrated with a strategy that preserves ventricular coordination. This distinction makes it possible to interpret individual blocks within a unified framework without assigning the same risk to all of them.

Organization of the conduction system and significance of conduction delays

Activation originating in the sinus node reaches the atrial myocardium and spreads through preferential propagation pathways whose integrity contributes to coordination of the two atria. The atrioventricular node physiologically slows the impulse before it travels through the His bundle, bundle branches, and Purkinje network. Distal distribution is rapid and allows large portions of the ventricles to activate within a short interval. Nodal delay therefore has a physiologic function, whereas substantial delay in the distal network may alter the sequence of contraction or prevent impulses from reaching the myocardium.

Decremental conduction in the atrioventricular node depends on its cellular properties and recovery after each activation. Increases in atrial rate, vagal stimulation, and some drugs may accentuate it. The His-Purkinje system has different properties: rapid depolarization and organized connections permit high propagation velocity, which may decrease in the presence of fibrosis, ischemia, ion-channel abnormalities, or metabolic imbalances. The relatively favorable significance of functional nodal slowing should therefore not be transferred automatically to distal conduction.

On the surface electrocardiogram, the PR interval includes the time from the onset of atrial activation to the onset of ventricular activation. It does not measure exclusively transit through the atrioventricular node. P-wave duration provides information on atrial depolarization; QRS duration, axis, and morphology describe the ventricular activation sequence. Combined interpretation is more informative than any single number: a prolonged PR interval with a narrow QRS and a prolonged PR interval associated with bifascicular block require different reasoning, even though part of the delay in both cases may be nodal.

Intracardiac recordings further separate the components of electrical transit. The AH interval mainly reflects atrionodal conduction, whereas the HV interval assesses the time from the His bundle to the earliest ventricular activation. These measurements help identify distal disease when the surface ECG cannot localize the disorder reliably. Their use should answer a concrete clinical question, for example unexplained syncope with bundle-branch block; they are not a mandatory step for every incidental PR or QRS abnormality.

The activation rate also modifies the behavior of diseased tissue. Some blocks appear during acceleration of the rhythm, when impulses arrive before conduction has recovered; others emerge in relation to pauses or slowing through more complex distal mechanisms. Intermittence does not prove benignity. A normal ECG between two episodes may coexist with clinically important impairment that becomes visible only during symptoms, exercise, or prolonged monitoring.

Major electrocardiographic phenotypes and their relationships

Disorders of atrial propagation may alter P-wave duration and morphology. Interatrial block reflects abnormal electrical communication between the atria, whereas sinoatrial block concerns exit of the impulse from the sinus node. These two conditions are not equivalent and should not be confused with simple slowing of sinus rate. Atrial abnormalities may accompany atrial cardiomyopathy and be associated with supraventricular arrhythmias, but their recognition alone does not justify either a diagnosis of atrial fibrillation or anticoagulant therapy.

Atrioventricular block instead describes atrioventricular conduction that is slowed, intermittently interrupted, or completely interrupted. In first-degree block, all impulses reach the ventricles with a prolonged PR interval; in second-degree block, some impulses are not conducted; in complete block, effective transmission of atrial impulses is absent. This classification describes the relationship between atria and ventricles but must be integrated with the site of the disorder. The same conduction ratio may result from nodal block or a distal lesion, with different prognostic implications.

Bundle-branch blocks alter the order in which the ventricles are activated. In right bundle-branch block, right ventricular depolarization is delayed; in left bundle-branch block, left ventricular activation follows an abnormal sequence that may be associated with mechanical dyssynchrony. Analysis cannot be limited to QRS width: morphology in the different leads, clinical context, and comparison with previous tracings are required. A wide QRS may also result from ventricular pacing, pre-excitation, ventricular origin of the rhythm, or metabolic abnormalities.

Fascicular blocks involve components of the left bundle branch and often manifest mainly as changes in the electrical axis. Association of right bundle-branch block and left fascicular block constitutes a form of bifascicular block. Addition of a long PR interval does not necessarily demonstrate impairment of the residual fascicle because the delay may be located in the atrioventricular node. The expression “trifascicular block,” used without clarifying the finding and suspected level, may therefore imply an anatomical precision that the ECG does not possess.

Alternating bundle-branch block, with documentation of different block configurations at different times, is a particularly important sign of extensive His-Purkinje disease. By contrast, a stable asymptomatic bundle-branch block does not automatically imply a need for pacing. Distinguishing an isolated disorder, multisegment involvement, and documented progression is central: it identifies both conditions that require protection from loss of conduction and those in which the main problem is associated heart disease.

Functional, structural, systemic, and iatrogenic causes

Degenerative fibrosis of the conduction system is a common cause of progressive abnormalities in adults and older people. It may involve the His bundle, bundle branches, and surrounding tissue, sometimes in association with calcification of the valvular apparatus. The diagnosis remains clinical after appropriate assessment because older age does not exclude treatable causes. In a younger person, important conduction disease instead requires particular attention to familial disorders, cardiomyopathies, neuromuscular diseases, and inflammatory or infiltrative processes.

Myocardial ischemia may impair conduction directly or through autonomic and metabolic changes. In inferior myocardial infarction, nodal and potentially transient mechanisms often predominate; distal block in the setting of anterior infarction may indicate extensive septal injury. These associations guide interpretation but do not replace individual analysis. Chest pain, instability, new ST-segment changes, or ventricular dysfunction requires evaluation of the coronary event rather than assuming that every electrical change results from chronic conduction disease.

Myocarditis, sarcoidosis, and infiltrative diseases may affect both the myocardium and specialized conduction system. Unexplained atrioventricular block, especially when associated with ventricular arrhythmias or dysfunction, may be the first cardiac manifestation. In familial forms, the combination of an electrical disorder, cardiomyopathy, and sudden death among relatives directs targeted genetic assessment. Identifying the disease changes treatment: protection from bradycardia may be insufficient when there is also substantial risk of ventricular tachyarrhythmias.

Drug-related causes include substances that slow the atrioventricular node and drugs that depress conduction in the fast conduction system. Beta-blockers, verapamil, diltiazem, and digoxin act mainly on the nodal component; some antiarrhythmic agents may accentuate a distal disorder. The effect depends on dose, combinations, renal function, and the pre-existing substrate. A block that appears during therapy may be caused by the drug or unmasked by it: normalization after withdrawal does not always exclude residual vulnerability and requires interpretation of the subsequent course.

Reversible conditions include hyperkalemia, hypothermia, acid-base abnormalities, and some endocrine disorders. Sleep, athletic training, and vagal reflexes may slow nodal conduction without structural injury. Cardiac surgery, ablation, and transcatheter aortic valve implantation may instead injure or compress structures near the conduction system. In these settings, timing of onset, evolution over the following hours, and the type of procedure are decision-relevant; a new disorder requires surveillance proportionate to the possibility of progression or recovery.

Clinical manifestations and diagnostic pathway

Consequences depend on ventricular rate, pauses, and synchronization. Loss of impulses may cause fatigue, reduced exercise tolerance, presyncope, or syncope; prolonged pauses may cause sudden loss of consciousness and trauma. Marked atrioventricular slowing may impair filling even without severe bradycardia. In bundle-branch block, by contrast, heart rate may remain normal while dyssynchrony contributes, in predisposed patients, to inefficient contraction and heart failure. The absence of palpitations therefore does not exclude a significant disorder.

The temporal history should reconstruct onset, frequency, and circumstances of symptoms, including exercise, rest, sleep, pain, meals, treatment changes, and recent procedures. Syncope without prodromes in a patient with a conduction disorder deserves particular attention, but not every faint is caused by block. Orthostatic hypotension, vasodepressor reflexes, and other arrhythmias may coexist. Comparison with old ECGs can separate a stable configuration from a new or progressive abnormality, often with greater utility than an isolated highly sophisticated test.

The twelve-lead ECG is the starting point. Atrial activity, sinus rate and regularity, PR interval, relationship between P waves and QRS complexes, and ventricular duration and morphology should be verified. Automated recordings may confuse blocked premature atrial contractions, artifacts, and sinus pauses with atrioventricular block. If episodes are intermittent, the monitoring device should be chosen according to their frequency: a short Holter may suffice for daily symptoms, whereas rare events require longer recordings and, in appropriate cases, an implantable loop recorder.

Echocardiography looks for dysfunction, valvular disease, and signs of structural heart disease. Cardiac magnetic resonance and, for selected indications, metabolic imaging help characterize inflammation, infiltration, or scar. Blood tests should answer plausible hypotheses, including electrolytes, renal function, and endocrine or infectious investigations when the context justifies them. An indiscriminate battery of tests does not replace etiologic reasoning and increases the likelihood of incidental results that are difficult to interpret.

Exercise testing may clarify symptoms during activity, adaptation of the PR interval, and development of block at increasing rates, provided the patient is stable and testing is performed with appropriate monitoring. Electrophysiological study is reserved for selected questions, including localization of distal impairment in the presence of syncope and bundle-branch block. A negative result does not exclude every intermittent block: the subsequent strategy depends on residual clinical probability, severity of episodes, and the ability to document them over time.

Treatment, pacing, and preservation of cardiac function

In a patient with hemodynamic instability attributable to bradycardia, the priority is to support perfusion and correct the cause. Monitoring, vascular access, and availability of pacing should accompany treatment. Atropine may be effective in nodal or vagal disorders but is less reliable in distal lesions; its administration should not delay necessary pacing. Transcutaneous pacing, chronotropic drugs, and temporary transvenous pacing are used according to severity, mechanism, and response, with verification of electrical capture and circulatory improvement.

Etiologic correction may resolve some blocks: treatment of metabolic imbalances, medication review, reperfusion when indicated, and treatment of infectious or inflammatory disease are integral parts of management. The possibility of recovery does not justify waiting without protection in an unstable patient. Conversely, a potentially reversible cause does not always permit prediction of complete normalization: the disorder may persist because of structural injury or recur when conduction tissue is already compromised.

The indication for a permanent pacemaker depends on the type of block and risk, not only on the minimum recorded heart rate. In acquired, nonreversible advanced, complete, or Mobitz II atrioventricular block, protection may be indicated even in the absence of symptoms. In first-degree delay and nodal Wenckebach phenomena, by contrast, the decision requires a convincing clinical relationship or specific risk circumstances. Isolated bundle-branch block alone is not a general indication for implantation.

System selection should consider atrial rhythm, ventricular function, and expected pacing burden. In patients in sinus rhythm, preserving an appropriate atrioventricular relationship may improve cardiac-cycle physiology. When frequent ventricular pacing is expected, the risk of dyssynchrony induced by conventional pacing should be assessed. Conduction-system pacing and biventricular resynchronization are different options selected according to ventricular function, QRS morphology, clinical indication, feasibility, and quality of available evidence.

Cardiac resynchronization therapy is not intended for every wide QRS, just as His-bundle pacing or left bundle-branch area pacing does not eliminate every technical limitation or complication. Choice requires balancing expected benefit, thresholds, reliability, anatomy, and follow-up requirements. In some cardiomyopathies, the device must also provide protection from ventricular arrhythmias. Separating the pacing indication from any defibrillation indication prevents a pacemaker from being considered a complete solution to different prognostic problems.

Prognosis, surveillance, and special situations

Prognosis is determined jointly by the conduction disorder and the disease that underlies it. Functional nodal slowing may have a favorable course; progressive His-Purkinje disease may expose the patient to sudden block; a new left bundle-branch block may be a marker of ventricular disease. There is therefore no single severity scale applicable to every finding. Symptoms, probable level, clinical evolution, ventricular function, and family history determine the need for further investigation and surveillance.

During follow-up without a device, the objective is to recognize clinical and electrical changes that are useful for decision-making. Development of syncope, exercise intolerance, new QRS abnormalities, or progression in the degree of block requires reassessment. Follow-up intervals depend on risk rather than an identical schedule for everyone. A stable, probably functional finding requires a different pathway from progressive familial disease, even when both patients report no symptoms at the first visit.

After implantation, follow-up should include device function and cardiac function. Thresholds, sensing, lead integrity, pacing percentage, and stored arrhythmias should be interpreted together with symptoms and echocardiography. A high burden of right ventricular pacing or chronic left bundle-branch block may justify surveillance of ventricular function. Remote monitoring facilitates identification of some problems but does not replace clinical assessment when dyspnea, syncope, local pain, or signs of infection develop.

In athletes, a prolonged PR interval or Wenckebach at rest may reflect autonomic adaptation; persistence during activity, symptoms, family history, or associated abnormalities require investigation. In children, normal intervals and the significance of heart rates depend on age, while congenital heart disease and maternal autoimmunity create specific scenarios. During pregnancy, management should consider maternal hemodynamic status, underlying disease, and characteristics of procedures without assuming that an isolated electrical finding automatically mandates restrictions or a device.

Shared decisions should clarify which event is intended to be prevented, which symptoms might improve, and which aspects of the disease will remain under care. Patients benefit from concrete instructions about reassessing symptoms and managing therapies. In inherited forms, the pathway may extend to relatives through counseling and targeted testing. Accurate diagnosis of site and context thus allows proportionate protection, avoiding both underestimation of unstable conduction and treatment of a physiologic adaptation as advanced disease.

References
  1. Glikson M et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. European Heart Journal. 2021;42(35):3427-3520.
  2. Kusumoto FM et al. 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society. Heart Rhythm. 2019;16(9):e128-e226.
  3. Steinberg JS et al. 2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. Heart Rhythm. 2017;14(7):e55-e96.
  4. Chung MK et al. 2023 HRS/APHRS/LAHRS guideline on cardiac physiologic pacing for the avoidance and mitigation of heart failure. Heart Rhythm. 2023;20(9):e17-e91.
  5. Brignole M et al. 2018 ESC Guidelines for the diagnosis and management of syncope. European Heart Journal. 2018;39(21):1883-1948.
  6. Wilde AAM et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases. Europace. 2022;24(8):1307-1367.
  7. Tisdale JE et al. Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association. Circulation. 2020;142(15):e214-e233.
  8. Merino JL et al. Practical compendium of antiarrhythmic drugs: a clinical consensus statement of the European Heart Rhythm Association of the European Society of Cardiology. Europace. 2025;27(8):euaf076.
  9. Gorenek B et al. Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. Europace. 2014;16(11):1655-1673.
  10. Lampert R et al. 2024 HRS expert consensus statement on arrhythmias in the athlete: Evaluation, treatment, and return to play. Heart Rhythm. 2024;21(10):e151-e252.
  11. Antzelevitch C et al. Overview of Basic Mechanisms of Cardiac Arrhythmia. Cardiac Electrophysiology Clinics. 2011;3(1):23-45.
  12. Zeppenfeld K et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. European Heart Journal. 2022;43(40):3997-4126.
  13. Çinier G et al. Evaluation and Management of Asymptomatic Bradyarrhythmias. Current Cardiology Reviews. 2021;17(1):60-67.
  14. Joglar JA et al. 2023 HRS expert consensus statement on the management of arrhythmias during pregnancy. Heart Rhythm. 2023;20(10):e175-e264.

Nota informativa: le informazioni contenute in questa pagina hanno esclusivamente finalità informative e divulgative e non sostituiscono il parere, la diagnosi o il trattamento di un medico. In caso di necessità, rivolgersi sempre a un professionista sanitario qualificato.

Trasparenza sull'intelligenza artificiale: questa pagina è stata realizzata con il supporto di strumenti di intelligenza artificiale, utilizzati come ausilio nella produzione e nell'elaborazione dei contenuti.